RecruitingPHASE1, PHASE2NCT03556228
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Studying Adenoid cystic carcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- VM Oncology, LLC
- Principal Investigator
- Clinical DevelopmentVM Oncology
- Intervention
- VMD-928 100 mg Tablet(drug)
- Enrollment
- 242 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2018 – 2028
Study locations (15)
- Providence Medical Foundation (site 209), Santa Rosa, California, United States
- Hartford Hospital (site 210), Hartford, Connecticut, United States
- The George Washington University Cancer Center (site 212), Washington D.C., District of Columbia, United States
- Holy Cross Hospital (site 213), Fort Lauderdale, Florida, United States
- Memorial Cancer Institute at Memorial Healthcare Systems (site 132), Pembroke Pines, Florida, United States
- Englewood Hospital and Medical Center (site 202), Englewood, New Jersey, United States
- Summit Medical Group (site 205), Florham Park, New Jersey, United States
- Atlantic Health System, Morristown Medical Center (site 124), Morristown, New Jersey, United States
- Presbyterian Kaseman Hospital (site 208), Albuquerque, New Mexico, United States
- Weill Cornell Medicine, Cornell University (site 126), New York, New York, United States
- Taylor Cancer Research Center (site 204), Maumee, Ohio, United States
- Cancer Care Associates of York (site 206), York, Pennsylvania, United States
- The University of Texas MD Anderson Cancer Center (site 127), Houston, Texas, United States
- Utah Cancer Specialists (site 203), Salt Lake City, Utah, United States
- PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200), San Juan, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03556228 on ClinicalTrials.govOther trials for Adenoid cystic carcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07507578A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic CarcinomaFondazione IRCCS Istituto Nazionale dei Tumori, Milano
- RECRUITINGPHASE2NCT06781567Clinical Trial of HG146 Administered to Participants with Adenoid Cystic CarcinomaHitGen Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT04209660Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT04214366Adenoid Cystic Carcinoma and Carbon Ion Only IrradiationHeidelberg University
See all trials for Adenoid cystic carcinoma of the cervix uteri →